Eli Lilly announced a flurry of genetic-medicine deals: a licensing agreement for MeiraGTx’s AAV-AIPL1 retinal gene therapy and a major collaboration with Sanegene worth up to $1.2 billion to advance RNAi candidates for metabolic diseases using tissue-selective delivery. Company releases and industry reports framed the moves as a strategic push to diversify Lilly’s pipeline into rare ophthalmology and RNAi-enabled metabolic targets. Lilly’s MeiraGTx deal grants it global rights to a late-stage vision-restoring program and builds on Lilly’s recent genetic-meds investments. The Sanegene collaboration aims to pair Lilly’s development engine with Sanegene’s selective delivery technology to create liver- or tissue-selective RNAi drugs for obesity and related metabolic disorders. Financial terms include upfronts, milestones and commercial royalties. Analysts said the agreements reflect big pharma’s continued appetite for genetic modalities, combining in-licensing of late-stage assets with platform partnerships to de-risk discovery and speed clinical translation.